MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Experimental therapeutics"

  • MDS Virtual Congress 2020

    Therapeutic Benefits of Music for Three Types of Neurological Disorders: an fNIRS Study Protocol for Controlled Trial in Dalian, China, Part 1-Parkinson’s Disease

    LL. Pu, Z.H Liang, W.C Tang, F.Y Cong, B.W Zhang, N.K Qureshi, J. Ly, T. Li (Dalian, China)

    Objective: It is investigated that the external auditory stimuli affect motor synchronization and control in patients with PD,and further studied that how music therapy or other…
  • MDS Virtual Congress 2020

    A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson’s Disease on Stable Dopaminergic Treatment (TEAL Study)

    E. Rawner, J. Powell, S. Minami, K. Tang, V. Klutzaritz, E. McCaskill Newman, J. Hannestad (San Carlos, CA, USA)

    Objective: Assessment of efficacy and safety in subjects with Parkinson’s disease (PD) following treatment for 12 weeks with placebo or AKST4290, a highly specific and…
  • MDS Virtual Congress 2020

    Deep learning approach for Parkinson’s disease classification from facial expressions: A pilot feasibility study

    O. Phokaewvarangkul, P. Vateekul, D. Surangsrirat, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To apply deep learning and traditional machine learning approaches to images of different facial expressions from patients and controls to aid in the prediction…
  • 2019 International Congress

    Longitudinal analysis of the modified Hoehn and Yahr disease stage in PD-1101, a Phase 1b clinical study of VY-AADC01

    A. van Laar, R. Richardson, A. Sedkov, E. Fine, K. Bankiewicz, B. Ravina, P. Larson, C. Christine (Pittsburgh, PA, USA)

    Objective: To describe changes over the first year in disease severity and activities of daily living using modified Hoehn and Yahr (mH&Y) stage and UPDRS…
  • 2019 International Congress

    Investigation of the protective efficacy of alpha-synuclein-specific antibodies in a novel neuronal cell model for synucleinopathies

    A. Peukert, M. Höllerhage, W. Zago, G. Höglinger (Munich, Germany)

    Objective: To investigate the protective efficacy of different alpha-synuclein (α-Syn)-targeting antibodies in a new model of α-Syn cell-to-cell spread. Background: The 14 kDa protein α-Syn…
  • 2019 International Congress

    Translating Preclinical Data to a Human Equivalent Dose for AMT-130 AAV Gene Therapy for Early Manifest Huntington’s Disease

    M. Evers, M. de Haan, A. Valles-Sanchez, E. Sawyer, S. Gill, R. Roos, S. van Deventer, P. Konstantinova, J. Higgins (Amsterdam, Netherlands)

    Objective: To extrapolate the human equivalent dose (HED) for a Phase I/II clinical trial in adults to explore the safety, tolerability, and efficacy of striatally-administered…
  • 2019 International Congress

    The SUNRISE-PD Study, a clinical trial of AXO-LENTI-PD: a CNS-directed gene therapy for the treatment of Parkinson’s Disease

    G. Corcoran, P. Korner, J. Wright, Y. Mo, J. Benoit, K. Binley, J. Miskin, N. Tuckwell, D. Zamoryakhin, T. Foltynie, R. Barker, K. Mitrophanous, S. Palfi (New York, NY, USA)

    Objective: This presentation will provide an overview of the design and key objectives of the SUNRISE-PD study. Background: Parkinson’s disease (PD) is caused in part,…
  • 2019 International Congress

    MRI, Clinical, and Neuropathological Findings after Bilateral Intra-striatal Administration of rAAV5-miHTT in Non-human Primates

    J. Higgins, B. Blits, L. Spronck, A. Valles-Sanchez, M. Evers, S. van Deventer, P. Konstantinova, M. de Haan (Lexington, MA, USA)

    Objective: To assess the effects of intra-striatal administration of a huntingtin protein (HTT) lowering gene therapy in macaca fascicularis non-human primates (NHP). Background: The aggregation…
  • 2019 International Congress

    Procedural Memory Changes of Parkinson’s Disease Patients Post Participation in Boxing

    A. Ghaffar, R. Gallagher, C. Mcleod, A. Leder (Old Westbury, NY, USA)

    Objective: Can participation in a Rock Study Boxing program improve procedural memory in people with Parkinson’s disease (PD)? Background: Procedural memory is important for daily…
  • 2019 International Congress

    A safety, tolerability and biomarker update from an ongoing open-label extension study of RG6042 in adults with early manifest Huntington’s disease

    S. Tabrizi, B. Leavitt, P. Sanwald Ducray, E. Wild, V. Schlegel, G. Hooper, A. Nicotra, J. Chevure, A. Smith, R. Lane, F. Bennett, L. Boak, R. Doody, S. Schobel (London, United Kingdom)

    Objective: To present the safety, tolerability and biomarker effects of RG6042 (previously, IONIS-HTTRX) during an open-label extension (OLE) study in adults with early manifest Huntington’s…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley